This study using data of PESA demonstrated that HbA1c levels are associated with risk for subclinical atherosclerosis in low-risk individuals without diabetes, even at levels below the prediabetes threshold.
This prospective registry study in the US showed that only 17.1% of patients with ASCVD on LLT had their therapy intensified over the next 2 years. Only 31.7% of patients achieved LDL-c levels <70mg/dL at 2 years.
ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.
This analysis in a community-based cohort showed that elevated carotid intima-media thickness and interadventitial diameter and lower carotid distensibility were associated with increased risk of incident dementia.
This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.
The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.
In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.
AHA 2020 Prevalence of CAD in a Swedish population was 4 out of 10, using CCTA data from the SCAPIS cohort. A prediction model was developed to identify those with widespread atherosclerosis.
Three experts discuss the findings of the EVAPORATE study in detail and how to interpret these. The EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.
This study evaluated the independent and joint associations of elevated Lp(a) and family history of CHD with incident ASCVD and CHD events among asymptomatic subjects.
ASCVD event rate in PAD patients is similar as that in CHD patients, yet statin therapy was lower in PAD patients.
Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.